Hyperglycemia - Pipeline Review, H1 2017

Detailed TOC of Hyperglycemia - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperglycemia - Overview
Hyperglycemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperglycemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperglycemia - Companies Involved in Therapeutics Development
Mitsubishi Tanabe Pharma Corp
Hyperglycemia - Drug Profiles
Drugs to Inhibit ABHD6 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGH-10019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KR-62980 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize Glucagon Receptor for Hyperglycemia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperglycemia - Dormant Projects
Hyperglycemia - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer